Opendata, web and dolomites

PERIF SIGNED

Perivascular cells at the crossroads of inflammation, regeneration and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PERIF project word cloud

Explore the words cloud of the PERIF project. It provides you a very rough idea of what is the project "PERIF" about.

source    unexpected    mediated    scleroderma    industrialized    excessive    tissue    pericytes    birth    chronic    regeneration    activation    threatening    adult    invaders    regulation    fibrosis    damaged    recovery    roles    fibrous    scar    stromal    diversity    questions    nearly    lung    perivascular    functions    previously    blood    disease    settings    world    vessels    mediators    team    dystrophies    inappropriate    identification    medicine    mechanisms    profibrotic    wraps    avenues    discrete    beneficial    vascular    bowel    intend    drew    injury    area    injured    regulating    mesenchymal    cells    diseases    suggests    repair    hindered    liver    heal    relative    collectively    normal    paving    tissues    tumors    transiently    life    muscular    last    scarring    kidney    cancer    fight    cardiovascular    fibrotic    organisms    organ    protective    contaminated    inflammatory    biological    host    massive    partial    function    point    replaces    notable    usually    immune    half    eliminate    necrotic    harmful    survival    agent    data    wound    preventing    initially    foreign    mural    population    variously    generating    neutralize    deaths    functional    inflammation    therapeutic   

Project "PERIF" data sheet

The following table provides information about the project.

Coordinator
INSTITUT PASTEUR 

Organization address
address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724
website: http://www.pasteur.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙976˙100 €
 EC max contribution 1˙976˙100 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT PASTEUR FR (PARIS CEDEX 15) coordinator 1˙976˙100.00

Map

 Project objective

The survival of organisms requires the ability to repair tissues upon injury, as well as, after birth, to fight foreign invaders that may have contaminated the wound. This last function is mediated by a complex host response involving immune cells, blood vessels and inflammatory mediators that collectively intend to neutralize the harmful agent and eliminate damaged/necrotic tissue. Initially beneficial, this massive inflammatory response comes with a cost, and adult injured tissues usually heal with a scar, which is an area of fibrous tissue that transiently replaces normal tissue. In chronic settings, scarring can become excessive in a process called fibrosis, to the point of preventing functional recovery of the injured organ and be life threatening. Nearly half of all deaths in industrialized world are due to diseases involving inappropriate, often chronic, inflammatory and fibrotic responses, including lung, kidney and liver diseases, scleroderma, inflammatory bowel diseases, muscular dystrophies, cardiovascular diseases, and tumors. However our current knowledge of the biological processes regulating fibrosis is partial, which has hindered therapeutic advances in the field. Recent data from our team and others drew new attention on a discrete population of mesenchymal cells that wraps around vessels, variously called mural cells, perivascular cells or pericytes, as a major source for profibrotic stromal cells generating scar tissue. Previously known for their vascular protective functions, increasing evidence suggests new and unexpected roles for these cells also in inflammation, repair/regeneration, and cancer. These new findings raise a number of challenging questions relative to their functional diversity, as well as mechanisms of activation/ regulation in disease. The identification and specific targeting of functional subsets of mesenchymal perivascular cells may have notable impact in research and medicine, paving the way for new therapeutic avenues in inflammatory/fibrotic diseases and cancer.

 Publications

year authors and title journal last update
List of publications.
2018 Selene E. Di Carlo, Lucie Peduto
The perivascular origin of pathological fibroblasts
published pages: 54-63, ISSN: 0021-9738, DOI: 10.1172/JCI93558
Journal of Clinical Investigation 128/1 2019-07-25
2017 Igor Stzepourginski, Giulia Nigro, Jean-Marie Jacob, Sophie Dulauroy, Philippe J. Sansonetti, G?rard Eberl, Lucie Peduto
CD34 + mesenchymal cells are a major component of the intestinal stem cells niche at homeostasis and after injury
published pages: E506-E513, ISSN: 0027-8424, DOI: 10.1073/pnas.1620059114
Proceedings of the National Academy of Sciences 114/4 2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERIF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERIF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More  

TORYD (2020)

TOpological many-body states with ultracold RYDberg atoms

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More